ABSTRACT
INTRODUCTION
Ovarian cancer is the third most common of all female reproductive system cancer in terms of frequency, but it determines 50% of deaths. Diagnosis of ovarian cancer is relatively late, while the use of ultrasound examination and tumoral markers dosage (eg. CA125) promotes early detection of cancer. Clinical stage is the most important prognostic factor in ovarian cancer. Actually, the overall five year survival rate is 80% for stage I, 50% for stage II, 30% for stage III and less than 8% for stage IV (1) . As a consequence a correct staging is relevant, and imaging plays an important role with a better accuracy of Computed Tomogaphy (CT) and Magnetic Resonance (MR) in advanced stages than ultrasound (2 Table IV shows the comparison between the two imaging methods. PET/CT allowed a sensible reduction (40%) in the number of equivocal lesions. PET/CT improves the localization of lesions in 60% of patients with stage I and II ovarian cancer and the characterization with a 43% reduction of uncertain lesions (Table V) . PET/CT improves of 40% the localization and of 46% the characterization in patients with III stage ovarian cancer and improves of 60% the localization and of 32% the characterization in patients with IV stage (Tables VI  and VII) . Concordance of PET for localization was 89% (109/122) k = 0.82; Concordance for characterization was 90% (110/122) k = 0.84; the level of concordance of PET/CT for localization was 100% (122/122) k = 1.0; the level of concordance for characterization was 99% (121/122) k = 0.99.
DISCUSSION
The results of the present study show that PET/CT allows a better localization in 54% of lesions and a better characterization of tracer uptake in 40% of lesions with an higher interoperator reproducibility than PET. PET itself gives few informations on anatomic localization of lesions, making difficult to discriminate between areas of pathological uptake and physiological distribution of tracer (10, 11) .The hybrid PET/CT system produces multimodal images with anatomical morphological outline useful for a better spatial localization of tracer distribution Bristow reported a PET/CT accuracy of 81,8% in discriminating recurrent ovarian cancer (>1 cm) and a 83,3 % sensitivity (12). Sironi study analyzed the possible role of PET/CT in the evaluation of recurrent ovarian cancer and reported an high positive predictive value (89%) and a low negative predictive value (57%) (13) . Università degli Studi di Salerno
Detection and exact localization of recurrent lesions are critical for guiding management and determining the proper therapeutic approach, which may prolong survival. Fluorine 18 fluorodeoxyglucose positron emission tomography (PET) combined with CT is useful for detection of recurrent or residual ovarian cancer and for monitoring response to therapy. However, PET/CT may yield false-negative results in patients with small, necrotic, mucinous, cystic, or low-grade tumors. In addition, in the posttherapy setting, inflammatory and infectious processes may lead to false-positive PET/CT results. Despite these drawbacks, PET/CT is superior to CT and MR imaging for depiction of recurrent disease. (14) In the present study PET/CT showen a remarkably low percentage of uncertain localization (2% of lesions). In addition, characterization of lesions was improved by PET/CT. Thus, PET/CT not only allows a better localization of lesions but also plays a role in characterization. The improvement in both lesion localization and characterization was consistent in all stages of disease. These findings are in agreement with previously reported data (15) . Moreover, recent studies demonstrated that FDG-PET/CT is more accurate than CT and MR in the detection of lymph node metastasis in patients with ovarian cancer (16, 17) . CONCLUSIONS PET/CT improves the anatomical localization of lesions and the related characterization with a strong decrease of lesions considered uncertain and it shows an high reproducibility. Integrated FDG-PET/CT can be successfully used for diagnosis, staging, restaging, therapy monitoring and prognostic prediction of ovarian cancer. Università degli Studi di Salerno 
